LEXX

Lexaria Bioscience Corp

Sep 16 • 04:00PM ET

1.46

+0.16 12.31 %

Healthcare • Biotechnology • Canada • NASD

Peers: TLRY CRON IIPR TVRD CGC ACB OGI VFF APH OGEN

Index	-	P/E	-	EPS (ttm)	-0.66	Insider Own	8.19%	Shs Outstand	19.46M	Perf Week	46.03%
Market Cap	28.56M	Forward P/E	-	EPS next Y	-0.47	Insider Trans	3.46%	Shs Float	17.96M	Perf Month	78.16%
Enterprise Value	23.66M	PEG	-	EPS next Q	-0.17	Inst Own	11.75%	Short Float	2.29%	Perf Quarter	44.55%
Income	-11.39M	P/S	46.06	EPS this Y	-47.87%	Inst Trans	1.06%	Short Ratio	2.50	Perf Half Y	-0.48%
Sales	0.62M	P/B	5.12	EPS next Y	33.09%	ROA	-135.93%	Short Interest	0.41M	Perf YTD	-30.48%
Book/sh	0.29	P/C	6.17	EPS next 5Y	6.84%	ROE	-145.34%	52W High	3.47 -57.93%	Perf Year	-58.52%
Cash/sh	0.24	P/FCF	-	EPS past 3/5Y	20.09% 21.61%	ROIC	-202.01%	52W Low	0.77 88.41%	Perf 3Y	-53.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-13.72% 15.84%	Gross Margin	86.12%	Volatility	11.38% 9.96%	Perf 5Y	-82.62%
Dividend TTM	-	EV/Sales	38.16	EPS Y/Y TTM	41.28%	Oper. Margin	-1838.48%	ATR (14)	0.10	Perf 10Y	-68.69%
Dividend Ex-Date	-	Quick Ratio	3.90	Sales Y/Y TTM	-	Profit Margin	-1849.39%	RSI (14)	80.89	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.90	EPS Q/Q	-61.04%	SMA20	48.22%	Beta	0.83	Target Price	6.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	107.14%	SMA50	58.07%	Rel Volume	1.31	Prev Close	1.30
Employees	7	LT Debt/Eq	0.02	Earnings	Jul 18	SMA200	5.38%	Avg Volume	164.39K	Price	1.46
IPO	Oct 10, 2006	Option/Short	No / Yes	EPS/Sales Surpr.	-44.83% 27.01%	Trades		Volume	215,285	Change	12.31%

Aug-27-25 09:20AM	Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference (ACCESSWIRE)
Aug-15-25 09:25AM	Lexaria Bioscience announces last patient, last visit in Phase 1b GLP-1 study (TipRanks)
Aug-14-25 09:20AM	Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone (ACCESSWIRE)
Aug-06-25 09:20AM	GLP-1 "Arms Race" Broadens to Include Dozens of Companies (ACCESSWIRE)
Jul-28-25 09:25AM	Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study (ACCESSWIRE) -8.49%
09:25AM	Loading…
Jul-23-25 09:25AM	Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry (ACCESSWIRE) +6.19%
Jun-23-25 09:15AM	Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide (ACCESSWIRE)
Jun-12-25 09:15AM	Lexaria Bioscience announces completion of GLP-1-H25-5 study (TipRanks)
Jun-11-25 09:05AM	Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule (ACCESSWIRE)
Jun-05-25 09:20AM	Lexaria Attending BIO International Convention (ACCESSWIRE)
May-12-25 09:00AM	Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company (ACCESSWIRE)
Apr-28-25 04:15PM	Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -9.63%
Apr-25-25 08:00AM	Lexaria Announces $2 Million Registered Direct Offering of Common Stock (ACCESSWIRE) -20.12%
Apr-23-25 09:10AM	Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology (ACCESSWIRE) +8.90%
Apr-03-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) -8.38%
09:15AM	Loading…
Mar-18-25 09:15AM	Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R) (ACCESSWIRE) -5.25%
Feb-27-25 08:00AM	The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience (ACCESSWIRE)
Feb-24-25 08:00AM	Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm (ACCESSWIRE) +5.52%
Feb-20-25 08:00AM	Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide (ACCESSWIRE) -10.06%
Feb-11-25 08:00AM	Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy (ACCESSWIRE) -5.29%
Feb-06-25 09:40AM	Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway (ACCESSWIRE)
Feb-05-25 09:10AM	Lexaria Updates its Ongoing Human Study GLP-1-H24-4 (ACCESSWIRE) +5.08%
Jan-30-25 09:15AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-15-25 09:20AM	Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval (ACCESSWIRE)
Jan-14-25 09:10AM	Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R) (ACCESSWIRE) -6.31%
Dec-19-24 09:05AM	Lexaria's Registered GLP-1 Study #4 Begins Dosing (ACCESSWIRE)
Dec-18-24 09:25AM	Lexaria Forms New Scientific Advisory Board (ACCESSWIRE)
Dec-17-24 09:10AM	Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience (ACCESSWIRE)
Dec-10-24 09:43AM	Lexaria Bioscience engages CRO for human pilot study of DehydraTEHC-liraglutide (TipRanks)
Dec-09-24 09:10AM	Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5 (ACCESSWIRE)
11:00AM	Loading…
Nov-30-24 11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, and Surge Battery Metals (Newsfile)
11:00AM	BTV Features these Stocks to Watch: Contango Ore, First Nordic Metals, Champion Iron, Prime Mining, Lexaria Bioscience, Osisko Development, West Red Lake Gold Mines, & Surge Battery Metals (Newsfile)
Nov-26-24 09:20AM	Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs (ACCESSWIRE)
Nov-25-24 09:00AM	Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled (ACCESSWIRE)
Nov-20-24 09:05AM	ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study (ACCESSWIRE)
Nov-14-24 09:10AM	Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study (ACCESSWIRE) -6.19%
Nov-13-24 09:20AM	Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss (ACCESSWIRE)
Nov-07-24 09:15AM	Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments (ACCESSWIRE) +5.94%
Oct-24-24 09:10AM	Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-22-24 09:20AM	Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Oct-16-24 04:00PM	Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE)
Oct-15-24 08:25AM	Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -6.21%
Oct-09-24 09:05AM	Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing (ACCESSWIRE)
Oct-08-24 09:20AM	Lexaria Updates Current GLP-1 Market (ACCESSWIRE)
Oct-01-24 09:25AM	Lexaria Appoints Michael Shankman as Chief Financial Officer (ACCESSWIRE)
Sep-27-24 09:20AM	Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3 (ACCESSWIRE)
Sep-05-24 10:00AM	Lexaria Releases Strategic Letter from the Outgoing CEO (ACCESSWIRE)
09:00AM	Lexaria Welcomes Industry Veteran as New CEO (ACCESSWIRE)
Sep-03-24 08:30AM	Lexaria Enters a Material Transfer Agreement for DehydraTECH Research (ACCESSWIRE) -6.65%
Aug-29-24 09:25AM	Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral Capsules (ACCESSWIRE) +10.62%
Aug-27-24 09:20AM	First Results from Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Aug-22-24 09:20AM	Positive 8-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE) -7.90%
Aug-21-24 09:00AM	Positive Interim Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study (ACCESSWIRE)
Aug-19-24 09:05AM	Positive Results from Lexaria's Molecular Characterization Study (ACCESSWIRE)
Jul-17-24 10:30AM	Positive Interim Body Weight Results from Lexaria's Diabetes Animal Study (ACCESSWIRE)
Jul-16-24 09:20AM	Lexaria Preparing For Strategic Growth (ACCESSWIRE)
Jul-12-24 05:52PM	LEXX Stock Earnings: Lexaria Bioscience Misses EPS, Misses Revenue for Q3 2024 (InvestorPlace)
Jul-09-24 09:10AM	Dosing is Complete in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jul-08-24 09:10AM	Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating Epilepsy (ACCESSWIRE) -5.49%
Jun-24-24 06:40AM	7 A-Rated Penny Stocks to Beat June Gloom (InvestorPlace)
Jun-18-24 09:00AM	Lexaria Awards CRO Contract for 12-Week DehydraTECH GLP-1 Chronic Human Study (ACCESSWIRE)
Jun-14-24 07:15AM	7 A-Rated Biotech Stocks Worth Betting on in June (InvestorPlace) -6.08%
Jun-05-24 09:00AM	Dosing Continues in Lexaria's Second GLP-1 Human Pilot Study (ACCESSWIRE)
Jun-04-24 07:28AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
May-30-24 06:45AM	7 A-Rated Penny Stocks Work Betting On in H2 2024 (InvestorPlace) +5.00%
May-23-24 09:05AM	Lexaria Awards Contract For Third GLP-1 Human Pilot Study (ACCESSWIRE)
May-21-24 09:20AM	Lexaria Receives Two New Medical-Treatment Patents in Hypertension and Epilepsy (ACCESSWIRE)
May-17-24 09:10AM	Dosing Begins in Lexaria's Comprehensive GLP-1 Animal Study (ACCESSWIRE)
May-08-24 09:10AM	Lexaria Begins Dosing of Its Second GLP-1 Human Pilot Study (ACCESSWIRE)
May-06-24 09:05AM	Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 Drugs (ACCESSWIRE) +8.95%
Apr-30-24 03:40PM	Lexaria to Receive $4.7 Million Gross Proceeds in Warrant Exercise and Issuance (ACCESSWIRE) +25.61%
Apr-16-24 09:10AM	Lexaria Receives Ethics Review Board Approval to Begin New GLP-1 Study (ACCESSWIRE) +16.08%
Apr-09-24 09:52PM	LEXX Stock Earnings: Lexaria Bioscience Beats EPS for Q2 2024 (InvestorPlace) -8.78%
Apr-02-24 09:00AM	Lexaria Awarded New Patents (ACCESSWIRE)
Mar-21-24 09:20AM	Lexaria to Present at The LD Micro Invitational XIV (Newsfile) -7.03%
Mar-14-24 09:20AM	Lexaria Appoints Nelson Cabatuan as Chief Financial Officer (ACCESSWIRE) -12.50%
Mar-07-24 09:05AM	Lexaria Awards Contract For Next GLP-1 Human Pilot Study (ACCESSWIRE) +11.61%
Mar-05-24 09:05AM	Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1 (ACCESSWIRE) +12.67%
Mar-04-24 09:15AM	7% Weight Loss in Animals Supports Lexaria's Next 8-week Animal Study (ACCESSWIRE)
Mar-01-24 08:20AM	Lexaria Announces FDA Clearance for its Planned U.S. Phase 1b Hypertension Clinical Trial (ACCESSWIRE) -15.36%
Feb-16-24 04:05PM	Lexaria Announces Closing of $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.32% +8.41%
Feb-15-24 08:00AM	Lexaria Announces $3.6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (ACCESSWIRE) -9.23%
Jan-30-24 08:45AM	Lexaria's Submits Investigational New Drug Application (ACCESSWIRE)
Jan-24-24 08:45AM	Lexaria Releases Annual Letter from the CEO (ACCESSWIRE)
Jan-22-24 08:51AM	LEXX Stock Earnings: Lexaria Bioscience Reported Results for Q1 2024 (InvestorPlace)
Jan-16-24 09:10AM	Lexaria Unveils Extensive Planned 2024 GLP-1 Study Program (ACCESSWIRE)
Jan-11-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream (GlobeNewswire) +5.56%
Jan-10-24 08:30AM	GLP-1: Beyond Diabetes, a Blockbuster Horizon Beckons (PR Newswire)
Jan-09-24 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform (GlobeNewswire)
Jan-08-24 08:30AM	Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs (PR Newswire)
Jan-04-24 09:05AM	Lexaria's Patented Technology Improved the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide (ACCESSWIRE) +6.92%
Dec-07-23 09:20AM	Lexaria's Investigational New Drug Application Filing Update (ACCESSWIRE)
Nov-28-23 09:10AM	Lexaria's Technology Lowers Blood Glucose More Effectively than Rybelsus(R)-Branded GLP-1 drug Semaglutide Alone in Human Pilot Study (ACCESSWIRE)
Nov-27-23 09:05AM	Lexaria's Technology Improves the Oral Performance of the Rybelsus(R)-Branded GLP-1 drug Semaglutide in Human Pilot Study (ACCESSWIRE) +24.43%
Nov-01-23 08:30AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands Studies of Proprietary Platform in Multibillion-Dollar GLP-1 Drug Space (GlobeNewswire) +5.07%
08:30AM	Get Ready for Next Generation of Diabetes, Weight-Management Drugs (PR Newswire)
Oct-31-23 08:31AM	Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating Proprietary Drug-Delivery Platform for Improved Efficacy of GLP-1 Drugs (GlobeNewswire)
Oct-30-23 09:30AM	Can Diabetes, Weight-Loss Drugs Get Even Better (PR Newswire) +14.66%
Oct-13-23 09:05AM	Lexaria Enters New Global Exclusive Collaboration and License Agreement with SulfoSyn (ACCESSWIRE) -6.61%
Oct-12-23 09:10AM	Lexaria Granted Two New Patents in Canada (ACCESSWIRE)

Lexaria Bioscience Corp. is a biotechnology company, which engages in the provision of active pharmaceutical ingredients through its DehydraTECH drug delivery technology. It operates through the following segments: IP Licensing, B2B Product, Research and Development, and Corporate. The company was founded on December 9, 2004 and is headquartered in Kelowna, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
BUNKA CHRISTOPHER	Director	Jul 29 '25	Buy	0.92	15,600	14,375	270,012	Jul 30 05:12 PM
BUNKA CHRISTOPHER	Director	Jul 30 '25	Buy	0.91	11,900	10,866	281,912	Jul 30 05:12 PM
McKechnie William Edward	Director	Jul 29 '25	Buy	0.91	5,000	4,532	18,191	Jul 30 12:37 PM
DOCHERTY JOHN MARTIN	President & CSO	Jul 29 '25	Buy	0.93	5,376	4,989	5,376	Jul 30 11:34 AM
Carle Vanessa	Secretary	Jul 29 '25	Buy	0.91	750	682	750	Jul 30 11:23 AM
CHRISTOPHER RICHARD	Chief Executive Officer	Jul 29 '25	Buy	0.91	15,000	13,641	65,000	Jul 30 11:14 AM
CHRISTOPHER RICHARD	Chief Executive Officer	Dec 03 '24	Buy	2.47	27,172	67,175	50,000	Dec 03 02:03 PM
CHRISTOPHER RICHARD	Chief Executive Officer	Dec 02 '24	Buy	2.24	22,828	51,217	22,828	Dec 03 02:03 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LEXX

Lexaria Bioscience Corp

Upgrade your FINVIZ experience